Triptorelin (Decapeptyl SR) for premenopausal women with early endocrine responsive breast cancer

Record ID 32016000437
Authors' objectives: Breast cancer is the most common cancer in the UK. Most women who get breast cancer are over 50 years of age and have already gone through the menopause. However, younger women, and in rare cases, men, may also get breast cancer. There are many types of breast cancer. Triptorelin is a new treatment for a type of early breast cancer that usually occurs in younger women who have not gone through the menopause, and is described as hormone receptor-positive. Triptorelin is given as an injection straight into a muscle every 28 days along with hormonal therapy tablets that are already widely used for breast cancer. Studies at the moment are aiming to show how well these treatments work together and that triptorelin is safe to use. If triptorelin is licenced for use in the UK, it will provide a new treatment option for this patient group.
Project Status: Completed
Year Published: 2016
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Humans
  • Breast
  • Breast Neoplasms
  • Endocrine Gland Neoplasms
  • Female
  • Premenopause
  • Triptorelin Pamoate
Organisation Name: NIHR Horizon Scanning Centre
Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
Contact Email:
Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.